Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

NCT03974217 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Talazoparib
DRUG: Decitabine

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]